If you're trying to scare me for Halloween, I’m afraid of a full head of hair and an uninterrupted Sunday 🕺
2
20
4,208
An estimated 20 million U.S. men are affected by low testosterone. Today, Hims is broadening access to care with new injectable and oral TRT options for eligible men.
Read more from Pete Stahl, MD & SVP of Men’s Health here: bit.ly/4BhvQy3
Our AI clinical engine knows your treatment plan, your dose, and where you are in your care journey. After you opt in, it carries your context and helps you take action when you need to speak with a clinician.
Now, it's rolling out to Hims weight loss members. Hear more from CTO Mo Elshenawy: bit.ly/4rvSrT8
Five years ago: our first bell ringing. đź””
Today: We’re back at @NYSE, and we’re just getting started. 🚀
Hims Chief Medical Officer Anant Vinjamoori, MD on why frontline clinicians — who've watched real patients get better in real time — deserve a real seat at the table as the government weighs its decision on peptides, following last week's PCAC meeting: bit.ly/4xahL2B
Frontline clinicians have prescribed peptides, like the ones under FDA review, for years and watched real patients get better in real time.
That experience is exactly why I am so pleased that the FDA PCAC recommended moving forward on the majority of these peptides last week, and why the government should take that real-world clinical experience seriously as it finalizes its own decision.
Large randomized controlled trials may never happen for many of these compounds, because they're already known and unpatentable.
Trials can cost hundreds of millions of dollars, and companies may only be motivated to undertake that spend when a patent and years of exclusive pricing are waiting on the other side. That math simply doesn't work for these products.
I wrote more about why clinical experience deserves real weight and why we should strive to find a new path forward as we expand access to peptides in USA Today:
usatoday.com/story/opinion/v…
Not all telehealth platforms are created equal.
How can consumers tell the difference between a platform built for their health and one built for a quick sale?
Our latest article outlines 5 signs of safe, high-quality telehealth platforms—from access to clinical evaluations to ongoing provider support.
Learn more: bit.ly/4wajrc6
Side effects of being a #Knicks fan may include elevated heart rate, irrational confidence, emotional whiplash, and mild-to-severe hair thinning.
hims retweeted
Big News: Dr. Anant Vinjamoori is joining as the Chief Medical Officer of @wearehims!
An expert in longevity and preventive medicine, he’ll shape the clinical guidelines at Hims that help more men feel great at every stage of life.
Read more here: news.hims.com/newsroom/hims-…
hims retweeted
Canadians can now get digital prescriptions for 'generic Ozempic'
financialpost.com/news/retai…
hims retweeted
Generic semaglutide is now available for eligible Hims & Hers customers in Canada.
History shows that when generics enter the market, the whole landscape shifts. Prices fall, access expands, and quality care reaches people it never could before. We're proud to be on the frontlines of that change. 🇨🇦
Read more: news.hims.com/newsroom/hims-…
hims retweeted
Starting today, Hims & Hers is offering access to the full range of FDA-approved GLP-1 medication for eligible customers. Providers on our platform can now send prescriptions for Zepbound® and Foundayo™ to the LillyDirect® pharmacy, accessing self-pay pricing for our customers.
Read more on how we’re giving customers more options to support their health journey, and other important info:
news.hims.com/newsroom/full-…















